1.	Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) Versus Docetaxel as Second-Line Therapy in Patients With Progressive Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTI-PGT302, CWRU-CTI-1503, NCT00054184
2.	Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) Versus Gemcitabine or Vinorelbine in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2 Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTI-PGT304, NCT00054197
3.	Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2 Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTI-PGT303, NCT00054210
4.	Phase III Randomized Study of Paclitaxel Poliglumex Versus Paclitaxel in Women With Chemotherapy-Naïve Stage IIIB or IV Non-Small Cell Lung Cancer and Performance Status 2 Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CTI-PGT305, CTI-PIONEER, NCT00269828
5.	Phase I/II Study of CT-2103 in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-01024, CTI-1071, NCI-G01-1947, NCT00017017
6.	Phase II Study of Polyglutamate Paclitaxel (CT-2103) as Third-Line Treatment in Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0186C, NCT00045682
7.	Phase II CT-2103/Carboplatin in Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PGT201, NCT00069901
8.	Phase II Study of Paclitaxel Poliglumex (CT-2103; Xyotax™) and Capecitabine in Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0437, N0437, NCT00265733
9.	Efficacy and Safety Study of Xyotax to Treat Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: PCa-X-02, 03-0192-05, NCT00446836
10.	Phase II Study of Paclitaxel Poliglumex and Transdermal Estradiol in Patients With Androgen-Independent Stage IV Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: OHSU-2656, SOL-06048-L, NCT00459810
11.	Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-Small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: D-0433, NCT00487669
12.	Phase I Study of Polyglutamate Paclitaxel and Carboplatin in Patients With Chemotherapy-Naïve Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Carcinoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-9914, NCT00060359
13.	CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0133, NCT00270907
14.	A Pilot Study of PPX in Women With Metastatic Colorectal Cancer Phase: No phase specified Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 3C-07-3, NCT00598247